Background: Central neuromodulators, specifically tricyclic antidepressants (TCAs), are prescribed as prophylactic treatment for cyclical vomiting syndrome (CVS). It is unclear whether opioids and/or cannabis affect the treatment response to neuromodulators. The aims of this study were to assess: (i) the prevalence of opioid and cannabis use among outpatients with CVS, (ii) clinical characteristics associated with opioid/cannabis use and response to a three-tiered neuromodulator treatment algorithm, and (iii) the effect of opioid/cannabis cessation on response to the treatment algorithm.
Methodology: Data from consecutive patients newly diagnosed with Rome IV CVS at a single tertiary care neurogastroenterology outpatient clinic (January 2016-June 2024) were retrospectively collected. Patients were advised to stop consuming opioids and/or cannabis and commenced a low-dose TCA.
Results: Sixty-one (46/75) percent of outpatients with CVS responded to the three-tiered treatment algorithm. Among responders, 42 (91%) patients responded to TCA alone (1st line therapy), 3 (7%) patients responded to TCA and selective serotonin reuptake inhibitor or serotonin norepinephrine reuptake inhibitor (2nd line therapy), and 1 (2%) patient required topiramate (3rd line therapy). The mean [SD] dosage of TCA among responders was 26.5 [18.3] mg. Twenty-five (33%) patients consumed opioids, 14 (19%) took cannabis, and five (7%) consumed both opioids and cannabis. While opioid cessation was associated with clinical response to the treatment algorithm (p = 0.03), opioid intake at the initial consultation was not (p = 0.2). Irritable bowel syndrome was independently associated with significantly greater odds (OR [95% CI]) of opioid consumption at baseline (6.59 [1.49-29.24], p = 0.01). Heartburn was independently associated with lower odds of response to the treatment algorithm (0.2 [0.05-0.65], p = 0.006).
Conclusion: Low-dose neuromodulators, along with opioid and cannabis cessation, may be important strategies in the management of CVS.
Download full-text PDF |
Source |
|---|---|
| http://dx.doi.org/10.1111/nmo.70007 | DOI Listing |
Publication Analysis
Top Keywords
Similar Publications
Drug-Checking and Monitoring New Psychoactive Substances: Identification of the U-48800 Synthetic Opioid Using Mass Spectrometry, Nuclear Magnetic Resonance Spectroscopy, and Bioinformatic Tools.
Int J Mol Sci
February 2025
Centro de Investigação Interdisciplinar Egas Moniz, Cooperativa de Ensino Egas Moniz, 2825-084 Caparica, Portugal.
The misuse of opioids and opiates has remained a persistent issue since the 19th century. The recent resurgence of non-fentanyl synthetic opioids, such as U-type opioids and nitazenes, has further exacerbated the ongoing crisis. Identifying these synthetic opioids presents many challenges, including the emergence of new substances, the lack of standards, and the presence of structural isomers.
View Article and Find Full Text PDFAlcohol and Other Substance Screening in Bariatric Surgery Candidates: Utility of Self-Report and Toxicology Tests, Including Ethyl-Glucoronide.
Obes Surg
March 2025
Addiction Unit, Clinical Institute of Neurosciences (ICN), Hospital Clinic of Barcelona, C/Villarroel, 170, 08036, Barcelona, Spain.
Unlabelled: Following bariatric surgery (BS) patients have an increased risk of alcohol misuse.
Purpose: This 1-year cross-sectional study in potential BS candidates had several objectives: (a) assess the prevalence of risky drinking, alcohol use disorder (AUD), and other substance use/disorder; (b) compare the prevalence of these behaviors to that of the general Spanish population; (c) determine the proportion of patients with positive results in toxicology tests; and (d) study the predictive factors of risky drinking.
Setting: tertiary university hospital.
The repeatable battery for the assessment of neuropsychological status (RBANS) and substance use disorders: a systematic review.
Subst Abuse Treat Prev Policy
March 2025
Division of Mental Health and Addiction, Vestfold Hospital Trust, 2168, Tønsberg, Vestfold, 3103, Norway.
Background: Cognitive deficits are prevalent among substance use disorder (SUD) patients and affect treatment retention and outcome. The Repeatable Battery for the Assessment of Neuropsychological Status (RBANS) is a well-researched instrument in diverse patient groups and has the potential to serve as an effective and accurate method for identifying cognitive impairment in SUD patients. This systematic review examines the RBANS' ability to detect cognitive impairment in SUD patients.
View Article and Find Full Text PDFCB Cannabinoid Receptor Agonists Induce Acute Respiratory Depression in Awake Mice.
Pharmacol Res
March 2025
Department of Psychological and Brain Sciences, Indiana University Bloomington, Bloomington, IN, 47405 United States; Program in Neuroscience, Indiana University Bloomington, Bloomington, IN, 47405 United States; Gill Institute for Neuroscience, Indiana University, Bloomington, IN, 47405 United States. Electronic address:
Recreational use of synthetic cannabinoid agonists (i.e., "spice compounds") that target the cannabinoid type 1 receptor (CB) can cause acute respiratory failure in humans.
View Article and Find Full Text PDFWant AI Summaries of new PubMed Abstracts delivered to your In-box?
Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!